Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?

Key Takeaways MRK's Gardasil sales fell 39% year over year to $5.2B in 2025 amid sluggish demand.MRK halted Gardasil shipments in China as weak demand left partner Zhifei with above-normal inventory levels.MRK also saw lower demand for Gardasil in Japan and declines across several other vaccines in 2025.Merck (MRK) continues to face challenges with its second-largest product, Gardasil, which is a vaccine approved to prevent certain cancers caused by the human papillomavirus. While the vaccine’s sales grew s ...